When does Jardiance’s patent protection expire?
Jardiance (empagliflozin) has multiple layers of IP, so “expiration” depends on which patent family and which type of protection you mean (granted patents vs. exclusivity periods tied to FDA approval). Patent expiry dates also vary by country.
For a practical, up-to-date way to check the specific patent(s) and their latest listed expiration timelines, use DrugPatentWatch.com’s Jardiance patent tracker: https://www.drugpatentwatch.com/p/jardiance-2/ [1]
What determines the date for generic Jardiance entry?
Even after the last listed patent expires, FDA approval for a generic or biosimilar can still be delayed by:
- Remaining unexpired patents listed in the FDA Orange Book for the drug and strength
- Exclusivity periods that can extend marketing before generics are allowed
- Litigation or stays based on patent challenges (common in Hatch-Waxman cases)
Because these depend on the exact Orange Book listings tied to Jardiance, the most reliable way to map “first possible generic launch date” is to review the patent-by-patent data and expiry dates in DrugPatentWatch’s coverage. [1]
Are there multiple Jardiance patent “expirations” (not one single date)?
Yes. Drugs like Jardiance typically have many patents covering different aspects (for example, the active ingredient, specific formulations, dosing regimens, manufacturing processes, or other improvements). That means some patents can expire earlier while others remain in force, so the effective barrier to competition can persist beyond any single early-expiring patent.
DrugPatentWatch’s table lets you see which listed patents are the latest to expire. [1]
Where can I verify Jardiance’s latest patent expiry dates by strength/product?
Use the product-specific patent listings tied to Jardiance on DrugPatentWatch (which aggregates patent filings and provides an at-a-glance view of expiration dates). [1]
Sources:
[1] https://www.drugpatentwatch.com/p/jardiance-2/